Analysts at H.C. Wainwright Reconfirmed their Buy rating for Del Mar Pharmaceuticals (DMPI) with $12.0000 Target; Eagle Capital Management Trimmed By $4.02 Million Its Citigroup (C) Holding

June 27, 2018 - By Michael Collier

Citigroup Inc. (NYSE:C) Logo

The firm have set PT of $12.0000 on Del Mar Pharmaceuticals (DMPI) shares. This is 1,639.13% from the last price. In an analyst report revealed to investors on 27 June, H.C. Wainwright kept their Buy rating on shares of DMPI.

Eagle Capital Management Llc decreased Citigroup Inc (C) stake by 0.28% reported in 2018Q1 SEC filing. Eagle Capital Management Llc sold 60,014 shares as Citigroup Inc (C)’s stock declined 11.86%. The Eagle Capital Management Llc holds 21.33 million shares with $1.44 billion value, down from 21.39M last quarter. Citigroup Inc now has $169.11 billion valuation. The stock increased 0.87% or $0.57 during the last trading session, reaching $66.32. About 22.61M shares traded or 32.70% up from the average. Citigroup Inc. (NYSE:C) has risen 10.48% since June 27, 2017 and is uptrending. It has underperformed by 2.09% the S&P500. Some Historical C News: 18/05/2018 – Citi Back in Growth Mode in Brazil as It Leaves Retail Behind; 20/03/2018 – BBAM and Nomura Babcock & Brown Participate in a $870 Million Combined EETC JOLCO Transaction with British Airways; 22/05/2018 – Citigroup Plans to Sell $1B of Senior Floating Rate Notes Due 2024 and $350M of 4.45% Subordinated Notes Due 2027; 07/05/2018 – ValueAct Continues to Add to Citigroup Position ‘Opportunistically’ — Letter; 27/03/2018 – Citigroup Presenting at Conference Apr 20; 09/04/2018 – Latin American Bond Sales Decrease 16% This Year, Citi Leads; 07/03/2018 – VRIO CORP SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, CITIGROUP AND MORGAN STANLEY ARE AMONG UNDERWRITERS TO IPO; 26/04/2018 – British takeover regulator appoints Citigroup executive as director general; 01/05/2018 – Citywire: HSBC adds Citi investment counselor to Miami team; 18/04/2018 – CITI TO FIND NEW GLOBAL CORPORATE BANK HEAD FOR TECH GROUP

The stock increased 4.86% or $0.032 during the last trading session, reaching $0.69. About 522,327 shares traded or 167.71% up from the average. DelMar Pharmaceuticals, Inc. (DMPI) has declined 59.35% since June 27, 2017 and is downtrending. It has underperformed by 71.92% the S&P500. Some Historical DMPI News: 06/03/2018 – DELMAR INTL BUYS AIRTRADES FREIGHT FORWARDERS; 17/04/2018 – DELMAR PHARMACEUTICALS – NO DOSE-LIMITING TOXICITIES HAVE BEEN REPORTED FOLLOWING TREATMENT WITH MULTIPLE CYCLES OF VAL-083; 16/04/2018 – DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research; 22/03/2018 – I-newsource: Eyeballs, Del Mar and manure: More on HiCaliber Horse Rescue; 22/05/2018 – DelMar Appoints Saiid Zarrabian to Full-Time President and CE; 17/04/2018 – DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated; 24/05/2018 – DEL MONTE PACIFIC LTD DMPL.Sl – CONFIRMS DMPL’S UNIT, DMPI, RECEIVED PRE-EFFECTIVE APPROVAL FROM THE SEC ON IPO; 18/04/2018 – USGS: M 4.3 – 83km S of San Francisco del Mar, Mexico; 17/05/2018 – DelMar Pharmaceuticals 3Q Loss $2.93M; 22/05/2018 – DELMAR PHARMACEUTICALS – ZARRABIAN HAD PREVIOUSLY SERVED AS INTERIM PRESIDENT AND CEO SINCE NOVEMBER 2017

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. The company has market cap of $15.19 million. The Company’s product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which has completed Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. It currently has negative earnings. The firm has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the local delivery of combination chemotherapy for the treatment of brain cancer and other solid tumors.

Among 3 analysts covering DelMar Pharmac… (DMPI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. DelMar Pharmac… has $16 highest and $1100 lowest target. $13’s average target is 1784.06% above currents $0.69 stock price. DelMar Pharmac… had 11 analyst reports since January 5, 2017 according to SRatingsIntel. As per Thursday, January 4, the company rating was maintained by H.C. Wainwright. The company was maintained on Friday, June 23 by Maxim Group. H.C. Wainwright maintained DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) on Thursday, April 19 with “Buy” rating. H.C. Wainwright maintained DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) on Friday, June 23 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 30 report. The stock of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) earned “Hold” rating by Maxim Group on Monday, August 14. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, October 5. The rating was maintained by H.C. Wainwright on Wednesday, November 29 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $1200 target in Wednesday, May 23 report. The stock of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has “Buy” rating given on Monday, October 16 by H.C. Wainwright.

More recent DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) news were published by: Streetinsider.com which released: “Delmar Pharma (DMPI) Reports Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM” on June 26, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap” on June 22, 2018. Seekingalpha.com‘s news article titled: “DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2018 Results – Earnings Call Transcript” with publication date: May 31, 2018 was also an interesting one.

Analysts await DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) to report earnings on September, 26. They expect $-0.11 EPS, up 45.00% or $0.09 from last year’s $-0.2 per share. After $-0.13 actual EPS reported by DelMar Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -15.38% EPS growth.

Analysts await Citigroup Inc. (NYSE:C) to report earnings on July, 13. They expect $1.56 earnings per share, up 22.83% or $0.29 from last year’s $1.27 per share. C’s profit will be $3.98B for 10.63 P/E if the $1.56 EPS becomes a reality. After $1.68 actual earnings per share reported by Citigroup Inc. for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Since February 27, 2018, it had 0 insider buys, and 7 selling transactions for $5.91 million activity. Another trade for 7,000 shares valued at $536,410 was made by Callahan Don on Wednesday, February 28. Hu W. Bradford sold 8,010 shares worth $611,804. Shares for $937,571 were sold by Gerspach John C. Another trade for 6,466 shares valued at $500,666 was sold by Forese James A.. 32,400 shares were sold by Fraser Jane Nind, worth $2.51M on Tuesday, February 27. Another trade for 3,400 shares valued at $263,126 was sold by MURRAY JOSEPH MICHAEL.

More notable recent Citigroup Inc. (NYSE:C) news were published by: Seekingalpha.com which released: “Citigroup: The Largest CCAR Payout Among Mega-Cap Banks” on June 26, 2018, also Bizjournals.com with their article: “San Francisco fintech that cashes in home equity raises $40 million from global banks” published on June 26, 2018, Seekingalpha.com published: “Citigroup Will Thrive Regardless Of Interest Rates” on June 08, 2018. More interesting news about Citigroup Inc. (NYSE:C) were released by: Businesswire.com and their article: “Citi Appointed as Depositary Bank for Autolus Therapeutics’ ADR Programme” published on June 27, 2018 as well as Livetradingnews.com‘s news article titled: “Citigroup Inc. (NYSE:C) Bears in Favor” with publication date: May 30, 2018.

Among 41 analysts covering Citigroup Inc. (NYSE:C), 25 have Buy rating, 2 Sell and 14 Hold. Therefore 61% are positive. Citigroup Inc. had 127 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, July 17 by Nomura. Renaissance Macro Securities LLC maintained the shares of C in report on Sunday, July 16 with “Buy” rating. As per Thursday, March 15, the company rating was maintained by Morgan Stanley. Oppenheimer maintained Citigroup Inc. (NYSE:C) rating on Friday, October 16. Oppenheimer has “Outperform” rating and $72 target. As per Friday, October 13, the company rating was maintained by Nomura. The firm has “Buy” rating by Citigroup given on Friday, December 11. The firm has “Market Perform” rating given on Friday, October 13 by BMO Capital Markets. The firm has “Hold” rating given on Tuesday, June 6 by Jefferies. The firm has “Market Perform” rating by Oppenheimer given on Thursday, November 9. On Monday, December 21 the stock rating was initiated by Credit Suisse with “Neutral”.

Citigroup Inc. (NYSE:C) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.